Interestingly, in contrast to our results with GSK2181236A, Stasch et al. (2006) have shown that the vasodilatory effects of a different sGC activator, BAY 58-2667, are potentiated under pathophysiological conditions in animal models [aged SHR, hyperlipidemic (WHHL) rabbits and atherosclerotic (ApoEl−/−) mice] and humans (mesocolon arteries taken from patients with type 2 diabetes). The gene discussed is SGCB; the disease is type 2 diabetes mellitus.